Angiotensin II type 1 receptor blocker preserves tolerance to ischemia-reperfusion injury in Dahl salt-sensitive rat heart

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 6, 2008, Pages

  Matsuhisa, Seiji ^a   Otani, Hajime ^a   Okazaki, Toru ^a   Yamashita, Koji ^a   Akita, Yuzo ^a   Sato, Daisuke ^a   Moriguchi, Akira ^a   Imamura, Hiroji ^a   Iwasaka, Toshiji ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Antioxidant; Nitric oxide synthase

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LOSARTAN; MALONALDEHYDE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N(G) NITROARGININE METHYL ESTER; SERINE; TIOPRONIN; 4 HYDROXYNONENAL; 4-HYDROXY-2-NONENAL; ALDEHYDE; AMIDINE; BENZYLAMINE DERIVATIVE; ENOS PROTEIN, RAT; ENZYME INHIBITOR; N (3 (AMINOMETHYL)BENZYL)ACETAMIDINE; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; NOS2 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HYPERTENSION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SALT INTAKE; UPREGULATION;

ALDEHYDES; AMIDINES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIOXIDANTS; BENZYLAMINES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; HYPERTENSION; LOSARTAN; MALE; MALONDIALDEHYDE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PHOSPHORYLATION; RATS; RATS, INBRED DAHL; SODIUM CHLORIDE, DIETARY; THIOPRONINE; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 49249097922     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.91533.2007     Document Type: Article

References (33)

1. Bae SW, Kim HS, Cha YN, Park YS, Jo SA, Jo I. Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway. Biochem Biophys Res Commun 306: 981-987, 2003.
2. Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol 29: 207-216, 1997.
3. Bayorh MA, Ganafa AA, Socci RR, Eatman D, Silvestrov N, Abukhalaf IK. Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats. Am J Hypertens 16: 387-392, 2003.
4. Bolli R. The late phase of preconditioning. Circ Res 87: 972-983, 2000.
5. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33, 1897-1918, 2001.
6. Chen W, Gabel S, Steenbergen C, Murphy E. A redox-based mechanism for cardioprotection induced by ischemic preconditioning in perfused rat heart. Circ Res 77: 424-429, 1995.
7. Das DK, Maulik N, Engelman RM. Redox regulation of angiotensin II signaling in the heart. J Cell Mol Med 8: 144-152, 2004.
8. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605, 1999.
9. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 26: 691-697, 2003.
10. Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects. J Cardiovasc Pharmacol 24, Suppl 2: S6-S13, 1994.
11. Flynn JD, Akers WS. Effects of the angiotensin II subtype 1 receptor antagonist losartan on functional recovery of isolated rat hearts undergoing global myocardial ischemia-reperfusion. Pharmacotherapy 23: 1401-1410, 2003.
12. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 96: 2407-2413, 1997.
13. Horinaka S, Kobayashi N, Mori Y, Yagi H, Onoda M, Matsuoka H. Expression of inducible nitric oxide synthase, left ventricular function and remodeling in Dahl salt-sensitive hypertensive rats. Int J Cardiol 91: 23-35, 2003.
14. 2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32: 1787-1796, 1998.
15. Jones SP, Girod WG, Palazzo AJ, Granger DN, Grisham MB, Jourd'Heuil D, Huang PL, Lefer DJ. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol Heart Circ Physiol 276: H1567-H1573, 1999.
16. Kyoi S, Otani H, Matsuhisa S, Akita Y, Enoki C, Tatsumi K, Hattori R, Imamura H, Kamihata H, Iwasaka T. Role of oxidative/nitrosative stress in the tolerance to ischemia/reperfusion injury in cardiomyopathic hamster heart. Antioxid Redox Signal 8: 1351-1361, 2006.
17. Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl 24: S39-S43, 2006.
18. Matés JM, Pérez-Gómez C, Núñez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem 32: 595-603, 1999.
19. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83: 1182-1191, 1998.
20. Miki T, Miura T, Tsuchida A, Nakano A, Hasegawa T, Fukuma T, Shimamoto K. Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation. Circulation 102: 458-463, 2000.
21. Otani H. Reactive oxygen species as mediators of signal transduction in ischemic preconditioning. Antioxid Redox Signal 6: 449-469, 2004.
22. Ping P, Zhang J, Qiu Y, Tang XL, Manchikalapudi S, Cao X, Bolli R. Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res 81: 404-414, 1997.
23. Reimer KA, Murry CE, Jennings RB. Cardiac adaptation to ischemia. Ischemic preconditioning increases myocardial tolerance to subsequent ischemic episodes. Circulation 82: 2266-2268, 1990.
24. Sato M, Engelman RM, Otani H, Maulik N, Rousou JA, Flack JE 3rd, Deaton DW, Das DK. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation 102: III346 -III351, 2000.
25. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49: 241-248, 2007.
26. Tamura K, Chiba E, Yokoyama N, Sumida Y, Yabana M, Tamura N, Takasaki I, Takagi N, Ishii M, Horiuchi M, Umemura S. Renin-angiotensin system and fibronectin gene expression in Dahl Iwai saltsensitive and salt-resistant rats. J Hypertens 17: 81-89, 1999.
27. Varagic J, Frohlich ED. Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 34: 1435-1442, 2002.
28. Walsh EK, Huang H, Wang Z, Williams J, de Crom R, van Haperen R, Thompson CI, Lefer DJ, Hintze TH. Control of myocardial oxygen consumption in transgenic mice overexpressing vascular eNOS. Am J Physiol Heart Circ Physiol 287: H2115-H2121, 2004.
29. Wang C, Chiari PC, Weihrauch D, Krolikowski JG, Warltier DC, Kersten JR, Pratt PF Jr, Pagel PS. Gender-specificity of delayed preconditioning by isoflurane in rabbits: potential role of endothelial nitric oxide synthase. Anesth Analg 103: 274-280, 2006.
30. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 116: 535-544, 2007.
31. Ye Y, Lin Y, Perez-Polo R, Huang MH, Hughes MG, McAdoo DJ, Manickavasagam S, Uretsky BF, Birnbaum Y. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol 293: H813-H818, 2007.
32. Zhang J, Baines CP, Zong C, Cardwell EM, Wang G, Vondriska TM, Ping P. Functional proteomic analysis of a three-tier PKCε-Akt-eNOS signaling module in cardiac protection. Am J Physiol Heart Circ Physiol 288: H954-H961, 2005.
33. Zhao X, White R, Van Huysse J, Leenen FH. Cardiac hypertrophy and cardiac renin-angiotensin system in Dahl rats on high salt intake. J Hypertens 18: 1319-1326, 2000.